Profile data is unavailable for this security.
About the company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
- Revenue in USD (TTM)18.69m
- Net income in USD-6.72m
- Incorporated2000
- Employees100.00
- LocationMediwound Ltd42 Hayarkon StreetYAVNE 8122745IsraelISR
- Phone+972 89324010
- Fax+972 89324011
- Websitehttps://www.mediwound.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scpharmaceuticals Inc | 13.59m | -54.81m | 156.84m | 135.00 | -- | 4.20 | -- | 11.54 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 157.05m | 179.00 | -- | 0.6712 | -- | 1.60 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| ProQR Therapeutics NV | 14.55m | -28.96m | 161.08m | 157.00 | -- | 4.44 | -- | 11.07 | -0.3567 | -0.3567 | 0.1792 | 0.4459 | 0.0957 | -- | -- | 92,680.19 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 162.88m | 135.00 | -- | 6.10 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 164.01m | 93.00 | -- | 158.31 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 164.61m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 164.75m | 22.00 | -- | 3.33 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Renovaro Inc | 0.00 | -41.23m | 166.66m | 12.00 | -- | 1.80 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 166.88m | 84.00 | -- | 7.69 | -- | 47.68 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Mediwound Ltd | 18.69m | -6.72m | 167.53m | 100.00 | -- | 5.15 | -- | 8.97 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 168.19m | 3.00 | -- | 25.04 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| OptiNose Inc | 70.99m | -35.48m | 169.46m | 132.00 | -- | -- | -- | 2.39 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 171.38m | 101.00 | -- | -- | -- | 6.32 | -0.8755 | -0.8755 | 0.9574 | -- | -- | -- | -- | 268,299.50 | -- | -54.12 | -- | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | -- | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 172.28m | 147.00 | -- | -- | -- | 1.43 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 175.67m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Mediwound Ltd's reporting currency: US Dollar USD
18.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 485.99k | 5.12% |
| Yelin Lapidot Mutual Fund Management Ltd.as of 31 Mar 2024 | 287.83k | 3.03% |
| DAFNA Capital Management LLCas of 31 Mar 2024 | 188.75k | 1.99% |
| Uniplan Investment Counsel, Inc.as of 31 Mar 2024 | 146.11k | 1.54% |
| Essex Investment Management Co. LLCas of 31 Mar 2024 | 132.49k | 1.40% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 131.24k | 1.38% |
| Sargent Investment Group LLCas of 31 Mar 2024 | 124.41k | 1.31% |
| Point72 Asset Management LPas of 31 Mar 2024 | 121.16k | 1.28% |
| Silverberg Bernstein Capital Management LLCas of 31 Mar 2024 | 85.18k | 0.90% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 73.34k | 0.77% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
